Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021
David J. Elzi, William E. Bauta, Jamila R. Sanchez, Trisha Das, Shweta Mogare, Peter Zannes Fatland, Moises Iza, Alexander Pertsemlidis, Vivienne I. Rebel
The paper explains research that identified a novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells using the cellular receptor CD320, which is involved in the uptake of Vitamin B12. In addition to furthering the understanding of TCPP for use in diagnostics, bioAffinity’s research led to four patent applications protecting multiple novel therapeutic platforms for treating cancer.
“Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells” poster presented at International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021